Skip to main content
Log in

Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Background

Polypharmacy, as the use of five or more drugs, has commonly been associated with the elderly and multiple co-morbidities and related to impairment of clinical state and adverse outcomes, in general population. Limited data are available on the relationship between polypharmacy and adverse outcomes in atrial fibrillation (AF). We describe the prevalence of polypharmacy and AF, and its association with major adverse events, such as stroke and cardiovascular (CV) death.

Methods and results

For this study, we analysed all AFFIRM Trial patients with complete pharmacological data. Polypharmacy was recorded in 40 % of 4056 AF patients. The crude incidence of CV death was 3.45 % patient-years among patients with polypharmacy, vs 1.65 % patient-years without polypharmacy. Kaplan–Meier analysis showed that patients with polypharmacy had a higher cumulative incidence of CV death (p < 0.001). Cox regression analysis demonstrated that female gender (p = 0.038), diabetes mellitus (p = 0.029), previous myocardial infarction (MI) (p = 0.004), prior stroke (p = 0.011) and polypharmacy (p = 0.029) were independently associated with CV death. Polypharmacy was associated with an adjusted relative risk of 1.30 (95 % CI 1.03–1.64) for CV death. A linear increase in the number of drugs was significantly associated with CV death. No significant association was found with stroke occurrence.

Conclusions

Polypharmacy is highly prevalent in AF patients and associated with a worse clinical outcome, conferring 30 % excess relative risk for CV death. Thus, polypharmacy may be a health status marker. Strategies to reduce inappropriate prescription and polypharmacy should be tested in prospective longitudinal studies of AF patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mannucci PM, Nobili A (2014) Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Intern Emerg Med 9:723–734. http://www.ncbi.nlm.nih.gov/pubmed/25164413. Accessed 13 Apr 2015

  2. Nobili A, Licata G, Salerno F, Pasina L, Tettamanti M, Franchi C, Vittorio L De, Marengoni A, Corrao S, Iorio A, Marcucci M, Mannucci PM (2011) Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol 67:507–519. http://www.ncbi.nlm.nih.gov/pubmed/21221958. Accessed 15 Apr 2015

  3. Scott IA, Hilmer SN, Reeve E, Potter K, Couteur D Le, Rigby D, Gnjidic D, Mar CB Del, Roughead EE, Page A, Jansen J, Martin JH (2015) Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. http://www.ncbi.nlm.nih.gov/pubmed/25798731. Accessed 25 Mar 2015

  4. Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S (2009) Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging 26:1039–1048. http://www.ncbi.nlm.nih.gov/pubmed/19929031. Accessed 15 Apr 2015

  5. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby J V, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285:2370–2375. http://www.ncbi.nlm.nih.gov/pubmed/11343485. Accessed 2 Feb 2015

  6. Lip GYH, Laroche C, Dan G-A, Santini M, Kalarus Z, Rasmussen LH, Oliveira MM, Mairesse G, Crijns HJGM, Simantirakis E, Atar D, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP (2014) A prospective survey in European society of cardiology member countries of atrial fibrillation management: baseline results of EURObservational research programme atrial fibrillation (EORP-AF) pilot general registry. Europace 16:308–319. http://www.ncbi.nlm.nih.gov/pubmed/24351881. Accessed 15 Apr 2015

  7. Nobili A, Marengoni A, Tettamanti M, Salerno F, Pasina L, Franchi C, Iorio A, Marcucci M, Corrao S, Licata G, Mannucci PM (2011) Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med 22:597–602. http://www.ncbi.nlm.nih.gov/pubmed/22075287. Accessed 2 Apr 2015

  8. Raparelli V, Proietti M, Buttà C, Giosia P Di, Sirico D, Gobbi P, Corrao S, Davì G, Vestri AR, Perticone F, Corazza GR, Violi F, Basili S (2014) Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. Intern Emerg Med 9:861–870. http://www.ncbi.nlm.nih.gov/pubmed/24990547. Accessed 15 Apr 2015

  9. Anon (1997) Atrial fibrillation follow-up investigation of rhythm management—the AFFIRM study design. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. Am J Cardiol 79:1198–1202. http://www.ncbi.nlm.nih.gov/pubmed/9164885. Accessed 15 Apr 2015

  10. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833. http://www.ncbi.nlm.nih.gov/pubmed/12466506. Accessed 28 Feb 2015

  11. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272. http://www.ncbi.nlm.nih.gov/pubmed/19762550. Accessed 10 July 2014

  12. Lip GYH, Skjøth F, Rasmussen LH, Larsen TB (2015) Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc Score. J Am Coll Cardiol 65:1385–1394. http://www.ncbi.nlm.nih.gov/pubmed/25770314. Accessed 11 Mar 2015

  13. Piccini JP, Hellkamp AS, Mahaffey KW, Berkowitz SD, Nessel CC, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Breithardt G, Fox KA, Califf RM, Patel MR (2014) Abstract 15686: polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke: results from the ROCKET AF trial. Circulation 130:A15686. http://circ.ahajournals.org/content/130/Suppl_2/A15686.abstract?sid=abe3220c-b572-4430-8de5-55e196613209. Accessed 16 Oct 2015

  14. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2015) Heart disease and stroke statistics–2015 update: a report from the American heart association. Circulation 131(4):e29–322. http://www.ncbi.nlm.nih.gov/pubmed/25520374. Accessed 14 Apr 2015

  15. Prabhakaran S, Ruff I, Bernstein RA (2015) Acute stroke intervention. JAMA 313:1451. http://www.ncbi.nlm.nih.gov/pubmed/25871671. Accessed 14 Apr 2015

  16. Husted S, Caterina R de, Andreotti F, Arnesen H, Bachmann F, Huber K, Jespersen J, Kristensen SD, Lip GYH, Morais J, Rasmussen LH, Siegbahn A, Storey RF, Weitz JI (2014) Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 111:781–782. http://www.ncbi.nlm.nih.gov/pubmed/24658395. Accessed 15 Jan 2015

  17. Turagam MK, Velagapudi P, Flaker GC (2015) Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. Clin Interv Aging 10:1431–1444. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4562740&tool=pmcentrez&rendertype=abstract. Accessed 15 Sept 2015

  18. Marengoni A, Onder G (2015) Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ 350:h1059. http://www.ncbi.nlm.nih.gov/pubmed/25761379. Accessed 15 Apr 2015

  19. Dumbreck S, Flynn A, Nairn M, Wilson M, Treweek S, Mercer SW, Alderson P, Thompson A, Payne K, Guthrie B (2015) Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ 350:h949. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4356453&tool=pmcentrez&rendertype=abstract. Accessed 15 Apr 2015

  20. Kutner JS, Blatchford PJ, Taylor DH, Ritchie CS, Bull JH, Fairclough DL, Hanson LC, LeBlanc TW, Samsa GP, Wolf S, Aziz NM, Currow DC, Ferrell B, Wagner-Johnston N, Zafar SY, Cleary JF, Dev S, Goode PS, Kamal AH, Kassner C, Kvale EA, McCallum JG, Ogunseitan AB, Pantilat SZ, Portenoy RK, Prince-Paul M, Sloan JA, Swetz KM, Gunten CF Von, Abernethy AP (2015) Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness. JAMA Intern Med 175:691–700. http://www.ncbi.nlm.nih.gov/pubmed/25798575. Accessed 23 Mar 2015

  21. Moonen JEF, Foster-Dingley JC, Ruijter W de, Grond J van der, Bertens AS, Buchem MA van, Gussekloo J, Middelkoop HA, Wermer MJH, Westendorp RGJ, Craen AJM de, Mast RC van der (2015) Effect of discontinuation of antihypertensive treatment in elderly people on cognitive functioning-the DANTE study Leiden: a randomized clinical trial. JAMA Intern Med. http://archinte.jamanetwork.com/article.aspx?articleid=2429535#.VdwcRedUPYU.facebook. Accessed 29 Aug 2015

  22. Benetos A, Rossignol P, Cherubini A, Joly L, Grodzicki T, Rajkumar C, Strandberg TE, Petrovic M (2015) Polypharmacy in the aging patient. JAMA 314:170. http://www.ncbi.nlm.nih.gov/pubmed/26172896. Accessed 14 July 2015

  23. Rossello X, Pocock SJ, Julian DG (2015) Long-term use of cardiovascular drugs. J Am Coll Cardiol 66:1273–1285. http://content.onlinejacc.org/article.aspx?articleid=2432956&resultClick=3. Accessed 8 Sept 2015

  24. Caterina R De, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GYH, Morais J, Rasmussen LH, Siegbahn A, Verheugt FWA, Weitz JI (2013) Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Thromb Haemost 110:1087–1107. http://www.ncbi.nlm.nih.gov/pubmed/24226379. Accessed 2 Mar 2015

  25. Gallego P, Roldan V, Marín F, Romera M, Valdés M, Vicente V, Lip GYH (2013) Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 110:1189–1198. http://www.ncbi.nlm.nih.gov/pubmed/24096615. Accessed 8 Apr 2015

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Marco Proietti or Gregory Y. H. Lip.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 20 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Proietti, M., Raparelli, V., Olshansky, B. et al. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol 105, 412–420 (2016). https://doi.org/10.1007/s00392-015-0936-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-015-0936-y

Keywords

Navigation